Neuroradiology, American Board of Radiology, 2008 Diagnostic Radiology, American Board of Radiology, 2003
EDUCATION
Fellowship
Neuroradiology, UCLA School of Medicine, 2003 - 2004
Residency
Radiology, UCLA School of Medicine, 1999 - 2003
Internship
Internal Medicine, VA Greater Los Angeles Healthcare System, 1998 - 1999
Medical Degree
MD, University of Illinois College of Medicine at Chicago, 1998
MORE INFORMATION
Research Interest
1. Brain tumors, in particular Glioblastoma
2. Physiologic Imaging Biomarkers of Treatment Response
3. Gene Expression (genomics) of Brain Tumor Imaging
Awards & Recognition
Berlex/NER Foundation Fellowship in Basic Science Research Award 2005-05.
Publications
1. Tsui HCT, Pope WB, Kim CS, Klein WL, Transient expression of adheron molecules during chick retinal development. J Neurobiol. 1992;23:720-738.
2. Pope W, Enam SA, Miller BE, Ghanbari HA, Klein WL. Phosphorylated tau isotope of Alzheimer’s disease is coupled to axonal development in the avian central nervous system. Exp Neurol. 1993;120:106-113.
3. Pope W, Lambert M, Leypold B, Seupaul R, Sletten L, Krafft G, Klein WL. Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human Neuroblastoma cell line SH-SY5Y. Exp Neurol. 1994;126:185-194.
4. Pope W, Sayre J, Perlina A, Villablanca JP, Mischel P, Cloughesy T. Magnetic Resonance Imaging Correlates of Survival in Patients with High Grade Gliomas. Am J Neuroradiol. 2005;26:2466-2474.
5. Morioka C, El-Saden S, Pope W, Duckwiler G, Bui A, Kangarloo H. Integration of HIS/RIS clinical document with PACS image studies for Neuroradiology. Proc SPIE. 2005;5748:318-325.
6. Chen W, Cloughesy T, Delaloye S, Czernin J, Kamdar N, Schiepers C, Pope W, Silverman DH. 18FDOPA PET Imaging of Brain Tumors Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy. J Nucl Med. 2006;47:904-911.
7. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MR Imaging in Patients with High Grade Gliomas Treated with Bevacizumab and Chemotherapy. Neurology. 2006;66:1258-1260.
8. Nael K, Ruehm SG, Michaely H, Pope W, Laub G, Finn JP, Villablanca P. High Spatial-Resolution CE-MRA of the Carotid Circulation with Parallel Imaging: Comparison of image quality between two image quality between two different acceleration factors at 3.0T. Invest Radiol. 2006;41:391-399.
9. Nael K, Villablanca JP, Saleh R, Pope W, Nael A, Laub G, Finn JP. Contrast-enhanced MR angiography at 3T in the evaluation of intracranial aneurysms: a comparison with time-of-flight MR angiography. Am J Neuroradiol. 2006;27;2118-21.
10. Nael K, Villablanca P, Pope WB, McNamara T, Laub G, Finn JP. Contrast- enhanced MR Angiography of the Supra-Aortic Arteries at 3.0 Tesla: Highly Accelerated Parallel Acquisition for Improved Spatial Resolution Over an Extended Field of View. Radiology. 2007;242(2):600-609.
11. *Carlson MJ, *Pope WB, Bronstein J, Lai A, Nghiemphu P, Mischel P, Liau L, Nelson S, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of VEGF and neuronal pentraxin 2. Clin Cancer Res. 2007;13(9):2592-2598. (*authors contributed equally to this work).
12. Chen W, Delaloye S, Geist C, Czernin J, Sayre J, Silverman D, Satyamurthy N, Pope W, Lai A, Cloughesy T. Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation with 18F-FLT PET: A Pilot Study. J Clin Oncol. 2007;25:4714-4721.
13. Nael K, Villablanca JP, Mossaz L, Pope W, Juncosa A, Laub G, Finn JP. 3.0T Contrast-enhanced MR Angiography in Evaluation of Patients with suspected Intracranial Aneurysms: A Comparison with multi-slice CT Angiography. Am J Roentgenol. 2008;190(2):389-95.
14. Nghiemphu P, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of Anticoagulation Use and Bevacizumab in Patients with Glioma. Neuro Oncol. 2008;10:355-60.
15. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients with Newly-diagnosed Glioblastoma Multiforme: Interim analysis of safety and tolerability. Int J Rad Oncol Biol Phys. 2008;71:1372-80.
16. Ananthnarayan S, Bahng J, Roring J, Lai A, Nghiemphu P, Cloughesy TF, Pope W. MR imaging findings in GBM patients during prolonged bevacizumab treatment. J Neuroncol. 2008;88(3):339-47.
17. Morioka C, El-Saden S, Pope W, Sayre J, Duckwiler G, Meng F, Bui A, Kangarloo H. A methodology to integrate clinical data for the efficient assessment of brain-tumor patients. Inform Health Soc Care. 2008:33(1):55-68.
18. Pope WB, Chen JJ, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between Gene Expression and Enhancement in Glioblastoma Multiforme: an Exploratory DNA Array Analysis. Radiology. 2008;249:268-277.
19. Ledezma C, Chen W, Sai V, Freitas B, Czernin J, Cloughesy T, Pope WB. 18F-FDOPA PET/MRI Fusion in Patients with Primary/Recurrent Gliomas: Initial Experience. Eur J Radiol. 2008;May28(e-pub ahead of print).
20. Nghiemphu P, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R and Cloughesy TF. Bevacizumab and Chemotherapy for the Treatment of Recurrent Glioblastoma: a Single Institution Experience. Neurology (accepted).
21. Pope W, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel P, Lai A, Nghiemphu P, Rahmanuddin S and Goldin J. ADC Histogram Analysis Predicts Response to Bevacizumab Treatment in Recurrent GBM. Radiology (in press).
22. Harley EM, Pope WB, Villablanca JP, Mumford J, Suh R, Mazziotta J, Enzmann D, and Engel S. Recruitment of Face Selective Cortex Across the Acquisition of Radiological Expertise. Cerebral Cortex (accepted).
23. Khanlou N, Mathern GW, Mitchell WG, Pope W, Salamon N, Yong WH, Vinters HV. Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. Human Path (accepted).
Referring a Patient to UCLA
Our staff will assist you in selecting the appropriate UCLA clinical department for your patient.